Pfizer · 6 hours ago
Early Development Group Lead (VP)
United States - Connecticut - Groton
Full-time
Onsite
Director/Executive
$330K/yr - $514K/yr
10+ years expPfizer is a leading biopharmaceutical company, and they are seeking an Early Development Group Lead (VP) to oversee the early pipeline in oncology. This role involves managing multiple Global Development Product Leads and directing clinical trials or research activities across early stage clinical development programs.
BiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
No H1B
Responsibilities
Serve as a group lead within Early Stage Development with strategic oversight of a substantial proportion of the early pipeline
Contribute to the cross-functional strategic development of early stage programs from pre-IND to end of Phase 1 proof of concept
Support business development assessments and diligence including design of clinical development plans
In some circumstances, serve as temporary coverage for Global Development Product Leads of early stage program(s), leading early stage product teams and clinical study teams, and providing appropriate medical monitoring for ongoing clinical studies on interim basis
Contribute to review of IND application documents, clinical protocols, investigator brochures, clinical study reports, and other regulatory documents
Collaborate with research and translational sciences to interpret how preclinical and nonclinical data may inform clinical strategy
Evaluation of safety, pharmacology, biomarker, and efficacy data from ongoing and completed studies
Contribute to review of manuscripts, abstracts and presentations for scientific meetings and advisory boards
Conduct literature reviews and prepare summaries to support clinical development programs
Medical resource for design and interpretation of clinical and preclinical programs to support existing and new development candidates
Collaborate with a variety of internal and external partners and stakeholders, such as HAs, clinical investigators, clinicians, scientists and key opinion leaders (KOLs)
Drive cross-functional initiatives to contribute to process improvements, training, and other workstreams to support the clinical development and the overall business
Oversee and manage Global Development Product Leads to ensure cross-functional collaboration, scientific excellence, efficiency, crisp decision-making, and appropriate risk mitigation
Serve as a leader who attracts, hires, motivates, and develops talents
Qualification
Required
Extensive experience in early stage clinical trial design and execution
Deep understanding of cross-functional drug development from preclinical through commercial stages
Strong executive leadership presence and the ability to work effectively with other cross-functional leaders
Strong track record of mentorship and/or management
Passion for helping patients with cancer and for the science of oncology
Collaborative with internal company leadership, external development partners and investigators/medical professionals
A team player, works well in a team environment both as a leader and a key contributor
Global perspective and mindset, with the ability to work effectively with colleagues from myriad cultures, backgrounds and geographies
MD or MD/PhD
Clinical oncology experience; Board certification in oncology and/or hematology preferred
10+ years industry experience in oncology drug development preferred
Preferred
Board certification in oncology and/or hematology preferred
10+ years industry experience in oncology drug development preferred
Benefits
401(k) plan with Pfizer Matching Contributions
Additional Pfizer Retirement Savings Contribution
Paid vacation
Holiday and personal days
Paid caregiver/parental and medical leave
Health benefits to include medical, prescription drug, dental and vision coverage
Company
Pfizer
Pfizer is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines.
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$38BKey Investors
Starboard Value
2025-11-21Post Ipo Debt· $6B
2024-10-07Post Ipo Equity· $1B
2023-05-16Post Ipo Debt· $31B
Leadership Team
Albert Bourla
Chief Executive Officer
Ian Read
Chief Executive Officer
Recent News
2026-01-23
2026-01-23
2026-01-23
Company data provided by crunchbase